NTHI

Business Context and Reporting Period

Company: NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2025
Business Overview: NeOnc is a clinical-stage biopharmaceutical company developing novel molecular technologies for treating central nervous system diseases, specifically intracranial malignancies like glioblastoma. Its lead product, NEO100, holds Orphan Drug and Fast Track designations from the FDA. The company listed on the Nasdaq Global Market on March 26, 2025.

Key Financial Metrics

Operating Expenses (Six Months 2025): Total operating expenses were $37,648,866. Significant components included Share-based compensation ($20,923,850) and Advisory fees ($11,737,806). Research and Development expenses were $1,675,554.

Cash Flow (Six Months 2025): Net cash used in operating activities was $(10,964,226). Net cash provided by financing activities was $11,024,372, primarily from the sale of common stock ($11,324,372).

Material Changes vs. Prior Period

• Revenue: Revenue decreased from $63,000 in the six months ended June 30, 2024, to $39,990 in the same period in 2025. Revenue was $0 for the three months ended June 30, 2025, compared to $20,000 in the prior year period.
• Net Loss: Net loss increased significantly to $(38,006,186) for the six months ended June 30, 2025, compared to $(7,460,982) in the prior year period. This increase is largely driven by non-cash share-based compensation and one-time advisory fees related to the Nasdaq listing.
• Operating Expenses: Total operating expenses surged to $37.6 million (six months 2025) from $2.9 million (six months 2024). The primary drivers were the recognition of $20.9 million in share-based compensation (RSUs) and $11.7 million in advisory fees upon listing.
• Interest Expense: Interest expense decreased to $(357,672) for the six months ended June 30, 2025, from $(2,559,456) in the prior year, as the related party bridge loan was converted to equity in June 2024.
• Restatement: The company restated its financial statements for the quarter ended March 31, 2025, correcting an overstatement of share-based compensation amortization. This adjustment reduced the previously reported Q1 2025 net loss by approximately $5.7 million.

Guidance, Outlook, Risks, and Unusual Items

Liquidity and Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. With only $125,039 in cash as of June 30, 2025, and an accumulated deficit of $88.6 million, management states it does not have sufficient capital to fund operations for the next 12 months without additional financing.

Financing Activities:

• Private Placement: In March 2025, the company raised approximately $11.6 million through a private placement of common stock at $16.00 per share.
• Subsequent Debt: In July 2025 (subsequent event), the company entered into convertible promissory notes for $4 million with a 20% OID.
• Equity Line: An Equity Purchase Agreement with Mast Hill Fund allows for up to $50 million in sales, though no transactions had occurred under this agreement as of June 30, 2025.

Unusual Items:

• Advisory Fees: A one-time fee of approximately $11.3 million was incurred upon the Nasdaq listing in March 2025 under an agreement with AFH Holdings and Advisory, LLC.
• Share-Based Compensation: Significant non-cash expense recognized due to the vesting of RSUs triggered by the listing date.

Risks and Contingencies:

• Legal Proceedings: The company has outstanding litigation settlement payables totaling approximately $4.7 million (including $4.0 million to Orient EuroPharma and $600,000 to a vendor), payable upon IPO completion or specific dates. As of the filing date, these remain unpaid.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, citing material weaknesses in segregation of duties, risk assessment, and related party transaction tracking.
• Joint Venture: A letter of intent was signed in June 2025 for a joint venture with Quazar Investments for Middle East expansion, with a potential $50 million investment, but the entity had not yet been formed as of August 13, 2025.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $125,039 cash balance against the $14.8 million in total liabilities and the stated inability to fund operations for 12 months.
• Debt and Settlement Obligations: Confirm the status of the $4.7 million in litigation settlement payables and the terms of the $4 million convertible notes issued in July 2025.
• Restatement Impact: Review the details of the Q1 2025 restatement regarding share-based compensation to understand the accuracy of current period reporting.
• Internal Controls: Assess the remediation plan for the material weaknesses in internal controls over financial reporting identified by management.
• Related Party Transactions: Scrutinize the $5.9 million accrued advisory fee to AFH Holdings and the terms of the related party loans and line of credit with HCWG.
• Equity Dilution: Monitor the potential dilution from the $50 million Equity Purchase Agreement with Mast Hill and the 3.01 million outstanding RSUs.